Research & Development
Research & Development
Our R&D Strategy Maximizes Patients’ Benefits
Teijin Pharma’s approach to research and development is multiple, not only for pharmaceuticals, medical devices or biomaterials, but also their integration to create complementary and synergistic benefits for patients, where no other manufacturers can find healthcare solutions.
We Create Novel Treatments by Leveraging Integrated Technologies
Teijin Pharma continuously develops technology-based revolutionary products to create novel treatments for, mainly, musculoskeletal, respiratory and cardiovascular and metabolic disorders. In addition, our technologies have built a unique, global Home Healthcare Business.
Pharmaceuticals in Our R&D Pipeline
As of the end of June, 2020
|Development code (Generic name)||Target disease||Form||Development stage|
|GGS-CIDP (Immune globulin (human))||Chronic inflammatory demyelinating polyradiculoneuropathy||Injection||Approved, August 2019|
|GGS-ON (Immune globulin (human))||Optic neuritis||Injection||Approved, December 2019|
|NT 201 (Incobotulinumtoxin A)||Upper limbs spasticity||Injection||Approved, June 2020|
|ITM-058 (Abaloparatide acetate)||Osteoporosis||Injection||NDA|
|ITM-014T (Lanreotide acetate)||Thyroid stimulating hormone-secreting pituitary adenoma||Injection||NDA|
|NT 201L (Incobotulinumtoxin A)||Lower limbs spasticity||Injection||PH Ⅲ|
|GGS-MPA (Immune globulin (human))||Microscopic polyangiitis||Injection||PH Ⅲ|
|TMX-049DN||Diabetic Kidney disease in type 2 diabetes||Tablet||PH Ⅱ（US）|
|TMX-049||Gout, hyperuricemia||Tablet||PH Ⅱ|
|TMX-67HK (Febuxostat)||Gout, hyperuricemia (pediatric patient)||Tablet||PH Ⅱ|
|JTR-161||Acute Stroke||Injection||PH I/Ⅱ|
|TCK-276||Rheumatoid arthritis||Tablet||PH I|
Our Network of Integrated Technologies
We Provide Hospital-quality Care with Ensured Safety at Home
Teijin Pharma’s Home Healthcare business has developed highly reliable, energy-saving process control technology, acoustic noise depression technology and user-friendly design technology to ensure safety and easy use of advanced medical equipment in the home for any patient. Additionally, we continue to expand our communications infrastructure, including the development of a novel IT system that offers enhanced remote monitoring of a patient’s medical condition while at home. We also have established a 24 hours-a-day 7 days-a-week patient support system that includes emergency support even during a natural disaster.